- Home
- BBIO vs RLI Comparison
BBIO vs RLI Comparison
Compare BBIO & RLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- RLI
- Stock Information
- Founded
- BBIO 2015
- RLI 1965
- Country
- BBIO United States
- RLI United States
- Employees
- BBIO N/A
- RLI N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- RLI Property-Casualty Insurers
- Sector
- BBIO Health Care
- RLI Finance
- Exchange
- BBIO Nasdaq
- RLI Nasdaq
- Market Cap
- BBIO 8.0B
- RLI 6.8B
- IPO Year
- BBIO 2019
- RLI 1985
- Fundamental
- Price
- BBIO $45.12
- RLI $72.26
- Analyst Decision
- BBIO Strong Buy
- RLI Hold
- Analyst Count
- BBIO 14
- RLI 8
- Target Price
- BBIO $58.85
- RLI $78.60
- AVG Volume (30 Days)
- BBIO 3.3M
- RLI 474.1K
- Earning Date
- BBIO 07-31-2025
- RLI 07-21-2025
- Dividend Yield
- BBIO N/A
- RLI 3.60%
- EPS Growth
- BBIO N/A
- RLI N/A
- EPS
- BBIO N/A
- RLI 3.03
- Revenue
- BBIO $127,415,000.00
- RLI $1,733,218,000.00
- Revenue This Year
- BBIO $102.05
- RLI N/A
- Revenue Next Year
- BBIO $54.69
- RLI $5.96
- P/E Ratio
- BBIO N/A
- RLI $23.85
- Revenue Growth
- BBIO N/A
- RLI 8.88
- 52 Week Low
- BBIO $21.72
- RLI $68.50
- 52 Week High
- BBIO $45.48
- RLI $91.15
- Technical
- Relative Strength Index (RSI)
- BBIO 77.53
- RLI 44.18
- Support Level
- BBIO $39.65
- RLI $70.90
- Resistance Level
- BBIO $45.18
- RLI $74.00
- Average True Range (ATR)
- BBIO 1.49
- RLI 1.17
- MACD
- BBIO 0.54
- RLI -0.12
- Stochastic Oscillator
- BBIO 99.13
- RLI 38.60
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About RLI RLI Corp. (DE)
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.